ELABELA acts as a protective biomarker in patients with atrial fibrillation

Chunhong Cui; Hongmei Zhou; Jin Xu

doi:10.21037/jtd-21-1728

ELABELA acts as a protective biomarker in patients with atrial fibrillation

J Thorac Dis. 2021 Dec;13(12):6876-6884. doi: 10.21037/jtd-21-1728.

Authors

Chunhong Cui^#^{1

2}, Hongmei Zhou^#³, Jin Xu³

Affiliations

¹ Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, China.
² Basic Medical College, Shanghai University of Medicine and Health Sciences, Shanghai, China.
³ Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

^# Contributed equally.

Abstract

Background: Atrial fibrillation (AF) is the most common type of clinical arrhythmia. An early diagnosis can be beneficial in the prevention of complications, such as heart failure (HF) and stroke. In this study, we revealed that ELABELA (ELA) acts as a protective factor in patients with arrhythmia and could serve as a prognostic marker for AF and its associated complication of HF.

Methods: We tested the expression level of potential biomarkers including matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and ELA with enzyme-linked immunosorbent assay (ELISA) in serum derived from 131 patients (patients with AF =103; patients with paroxysmal supraventricular tachycardia =28). The impact of clinical risk factors and biomarkers on AF occurrence was evaluated using binary logistic analysis.

Results: The ELA expression level was lower in AF patients than in the negative controls (P<0.0001). Expression of ELA was negatively correlated with brain natriuretic peptide (BNP) expression in all the samples. In the binary logistic analysis, high levels of BNP and lower levels of ELA were significantly associated with an increased risk of AF (P<0.0001) and could be used as prognostic markers for patients with AF.

Conclusions: Expression of ELA showed a protective role in AF patients. The ELA level was negatively correlated with BNP levels, which has been shown to predict a high risk of HF independently and consistently. Additionally, lower levels of ELA were associated with a high risk of AF and HF in patients with arrhythmia.

Keywords: ELABELA (ELA); matrix metalloproteinase-9 (MMP-9); tissue inhibitor of metalloproteinase-1 (TIMP-1); atrial fibrillation (AF); brain natriuretic peptide (BNP).